Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality. Many
patients die early during the course, and those who survive are at risk for dying late from
adverse cardiac remodeling and heart failure.
The initial ischemic damage to the myocardium initiates an intense inflammatory response in
promoting further cardiac dysfunction and heart failure. The investigators propose that an
antiinflammatory strategy based on blockade of Interleukin-1 will quench the inflammatory
response and lead to a more favorable cardiac remodeling process.